Reduce to patients the cost of the drug, Gleevec.
427
Supporters
Novatis developed this drug in the 1990s. In the years since then the price of the drug has increased astronomically. Novartis must have paid their research costs long ago, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep them alive. Our US representatives should work with FDA to pressure Novartis to reduce the cost of Gleevec.
This petition was delivered to:
- Novartis and US Representatives in Congress